Sergey Vladimirovich Chepanov

Sergey Vladimirovich Chepanov

Auto-generated profile, based on publicly available information

Sergey Vladimirovich Chepanov

D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint Petersburg, Russia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2021 in Journal of obstetrics and women's diseases
Verified
Journal Article
Closed access
PDF file
RKRoman V. Kapustin
Roman V. Kapustin
ETElizaveta Tcybuk
Elizaveta Tcybuk
SCSergey V. Chepanov
Sergey V. Chepanov
Elena AlekseenkovaElena Alekseenkova
Elena Alekseenkova
EKEkaterina Kopteeva
Ekaterina Kopteeva
OAOlga N. Arzhanova
Olga N. Arzhanova
AIM: The aim of this study was to evaluate soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) levels in the blood of women with various types of diabetes mellitus, depending on the correction method applied, and to determine the prognostic significance of the sFlt-1 / PlGF ratio for predicting the development of preeclampsia in this patient population. MATERIALS AND METHODS: We examined 140 pregnant women who were included in six main study groups: type 1 diabetes mellitus (with or without pregravid preparation), type 2 diabetes mellitus (diet therapy or insulin therapy), and gestational diabetes mellitus (diet therapy or insulin therapy). The comparison groups consisted of pregnant women with preeclampsia and patients without complications of pregnancy. Using electrochemiluminescence analysis, PlGF and sFlt-1 levels in the blood serum were determined twice, at 11+013+6 and 30+033+6 weeks of gestation. Statistical data processing was performed using the IBM SPSS Statistics version 23 and GraphPad Prism version 8.0 software packages. RESULTS: In the blood serum of pregnant women with diabetes mellitus in the first and third trimesters of pregnancy, we found an increase in sFlt-1 level and a decrease in PlGF level, as well as an increase in the sFlt-1 / PlGF ratio. These changes were most pronounced in individuals with type 1 diabetes mellitus without pregravid preparation and with type 2 diabetes mellitus on insulin therapy. In patients with pregestational types of diabetes mellitus, the sFlt-1 / PlGF ratio was a predictor of preeclampsia already in the early stages of pregnancy. Analysis of the ROC curve showed that the threshold sFlt-1 / PlGF ratio for predicting preeclampsia in pregnant women with diabetes mellitus in the first trimester was 32.5 (sensitivity 92.9%, specificity 50.0%) and in the third trimester 71.8 (sensitivity 85.7%, specificity 82.3%) with AUC 0.78 (95% CI 0.680.88) and 0.89 (95% CI 0.830.95), respectively. In the first trimester, the positive and negative predictive values of the sFlt-1 / PlGF ratio as a predictor of preeclampsia in pregnant women with diabetes mellitus were 63.3% and 97.6%, respectively; in the third trimester, 38.9% and 93.6%, respectively. CONCLUSIONS: Blood level alterations of PlGF and sFlt-1 are characteristic of patients with diabetes mellitus in the first and third trimesters of pregnancy. An increase in the sFlt-1 / PlGF ratio is associated with a higher incidence of unfavorable perinatal outcomes in women with impaired carbohydrate metabolism. Determination of the sFlt-1 / PlGF ratio is a valid method for predicting the development or absence of preeclampsia in women with diabetes mellitus.

15 December 2015 in Journal of obstetrics and women's diseases
Verified
Journal Article
Open access
PDF file
TSTat’yana Nikolaevna Shlyakhtenko
Tat’yana Nikolaevna Shlyakhtenko
EAEkaterina Anatol’yevna Alyab’yeva
Ekaterina Anatol’yevna Alyab’yeva
OAOl’ga Nikolaevna Arzhanova
Ol’ga Nikolaevna Arzhanova
SSSergey Alekseevich Sel’kov
Sergey Alekseevich Sel’kov
TPTamara Aleksandrovna Pluzhnicova
Tamara Aleksandrovna Pluzhnicova
SCSergey Vladimirovich Chepanov
Sergey Vladimirovich Chepanov
Цель исследования. Выяснить частоту встречаемости антифосфолипидных антител среди пациенток с репродуктивными неудачами и определить алгоритм ведения этих больных. Материалы и методы. Обследовано 2150 женщин, из них 1650 с привычным невынашиванием беременности в анамнезе, 450 женщин с бесплодием и 50 соматически и гинекологически здоровых женщин. Результаты. У женщин с отягощенным акушерско-гинекологическим анамнезом повышенные уровни АФА встречаются в 24 % наблюдений при привычном невынашивании беременности и в 20 % случаев при бесплодии. Прегравидарная подготовка и постоянный мониторинг состояния пациенток эффективно снижает частоту неблагоприятных исходов беременности. Выводы. Представлен опыт работы по ведению женщин с антифосфолипидным синдромом и привычной потерей плода. Показано, что адекватная оценка их состояния, прегравидарная подготовка, методичное и внимательное наблюдение в течение беременности позволяет довести беременность до рождения жизнеспособного плода.

1 January 2017 in Obstetrics, Gynecology and Reproduction
Verified
Journal Article
Open access
PDF file
MKM. I. Krivonos
M. I. Krivonos
MZM. S. Zainulina
M. S. Zainulina
EKE. A. Kornyushina
E. A. Kornyushina
SCS. V. Chepanov
S. V. Chepanov
SSS. A. Selkov
S. A. Selkov
USE OF INTRAVENOUS IMMUNOGLOBULIN WITHIN THE IVF/ICSI PROTOCOL IN WOMEN WITH INFERTILITY AND ANTIPHOSPHOLIPID ANTIBODIES

21 December 2020 in Akusherstvo i ginekologiia
Verified
Journal Article
Closed access
KKKhudovekova A.M. Khudovekova
Khudovekova A.M. Khudovekova
MMMozgovaya E.V. Mozgovaya
Mozgovaya E.V. Mozgovaya
NNNagorneva S.V. Nagorneva
Nagorneva S.V. Nagorneva
PVProkhorova V.S. Prokhorova V
Prokhorova V.S. Prokhorova V
SSSelkov S.A. Selkov
Selkov S.A. Selkov
CCChepanov S.V. Chepanov
Chepanov S.V. Chepanov

14 September 2024 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
AEAnna Egorova
Anna Egorova
SCSergei Chepanov
Sergei Chepanov
SSSergei Selkov
Sergei Selkov
IKIgor Kogan
Igor Kogan
Anton KiselevAnton Kiselev
Anton Kiselev
Genetic constructs must be delivered selectively to target tissues and intracellular compartments at the necessary concentrations in order to achieve the maximum therapeutic effect in gene therapy. Development of targeted carriers for non-viral delivery of nucleic acids into cells, including those in muscle, which is one of the most challenging tissues to transfect in vivo, remains a topical issue. We have studied ternary complexes of plasmid DNA and an arginine–histidine-rich peptide-based carrier coated with a glutamate–histidine-rich polymer bearing skeletal muscle targeting peptide (SMTP) for the gene delivery to muscle tissue. The relaxation of the ternary complexes after polyanion treatment was assessed using the ethidium bromide displacement assay. The developed polyplexes were used to transfect C2C12 myoblasts in full-media conditions, followed by analysis of their toxic properties using the Alamar Blue assay and expression analysis of lacZ and GFP reporter genes. After delivering plasmids containing the GFP and lacZ genes into the femoral muscles of mdx mice, which are model of Duchenne muscular dystrophy, GFP fluorescence and β-galactosidase activity were detected. We observed that the modification of ternary polyplexes with 10 mol% of SMTP ligand resulted in a 2.3-fold increase in lacZ gene expression when compared to unmodified control polyplexes in vivo. Thus, we have demonstrated that the developed DNA/carrier complexes and SMTP-modified coating are nontoxic, are stable against polyanion-induced relaxation, and can provide targeted gene delivery to muscle cells and tissues. The results of this study are useful for a range of therapeutic applications, from immunization to amelioration of inherited neuromuscular diseases.

29 March 2019 in Akusherstvo i ginekologiia
Verified
Journal Article
Closed access
CCChepanov S.V. Chepanov
Chepanov S.V. Chepanov
KKKrivonos M.I. Krivonos
Krivonos M.I. Krivonos
AAArzhanova O.N. Arzhanova
Arzhanova O.N. Arzhanova
STShlaсhtenko T.N. Shlaсhtenko T
Shlaсhtenko T.N. Shlaсhtenko T
SSSaidov N.KH. Saidov
Saidov N.KH. Saidov
PDPrevention And Treatment Of Recurrent Pregnancy Loss At Maternity Hospital No. 1 2 Center For Diagnosis
Prevention And Treatment Of Recurrent Pregnancy Loss At Maternity Hospital No. 1 2 Center For Diagnosis